TY - JOUR
T1 - Moving forward in carcinogenicity assessment
T2 - Report of an EURL ECVAM/ESTIV workshop
AU - Corvi, Raffaella
AU - Madia, Federica
AU - Guyton, Kathryn Z
AU - Kasper, Peter
AU - Rudel, Ruthann
AU - Colacci, Annamaria
AU - Kleinjans, Jos
AU - Jennings, Paul
PY - 2017/12
Y1 - 2017/12
N2 - There is an increased need to develop novel alternative approaches to the two-year rodent bioassay for the carcinogenicity assessment of substances where the rodent bioassay is still a basic requirement, as well as for those substances where animal use is banned or limited or where information gaps are identified within legislation. The current progress in this area was addressed in a EURL ECVAM- ESTIV workshop held in October 2016, in Juan les Pins. A number of initiatives were presented and discussed, including data-driven, technology-driven and pathway-driven approaches. Despite a seemingly diverse range of strategic developments, commonalities are emerging. For example, providing insight into carcinogenicity mechanisms is becoming an increasingly appreciated aspect of hazard assessment and is suggested to be the best strategy to drive new developments. Thus, now more than ever, there is a need to combine and focus efforts towards the integration of available information between sectors. Such cross-sectorial harmonisation will aid in building confidence in new approach methods leading to increased implementation and thus a decreased necessity for the two-year rodent bioassay.
AB - There is an increased need to develop novel alternative approaches to the two-year rodent bioassay for the carcinogenicity assessment of substances where the rodent bioassay is still a basic requirement, as well as for those substances where animal use is banned or limited or where information gaps are identified within legislation. The current progress in this area was addressed in a EURL ECVAM- ESTIV workshop held in October 2016, in Juan les Pins. A number of initiatives were presented and discussed, including data-driven, technology-driven and pathway-driven approaches. Despite a seemingly diverse range of strategic developments, commonalities are emerging. For example, providing insight into carcinogenicity mechanisms is becoming an increasingly appreciated aspect of hazard assessment and is suggested to be the best strategy to drive new developments. Thus, now more than ever, there is a need to combine and focus efforts towards the integration of available information between sectors. Such cross-sectorial harmonisation will aid in building confidence in new approach methods leading to increased implementation and thus a decreased necessity for the two-year rodent bioassay.
KW - Journal Article
UR - http://www.scopus.com/inward/record.url?scp=85030635655&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030635655&partnerID=8YFLogxK
U2 - 10.1016/j.tiv.2017.09.010
DO - 10.1016/j.tiv.2017.09.010
M3 - Article
C2 - 28911985
SN - 0887-2333
VL - 45
SP - 278
EP - 286
JO - Toxicology in Vitro
JF - Toxicology in Vitro
ER -